Webinar Invitation: Accelerating Globalized CMC Filing Strategy for ADC IND: Key Insights and Best Practices Can one ADC CMC package meet the IND expectations of both the FDA and NMPA? As more ADC programs pursue parallel IND filings in the US and China, regulatory alignment needs to begin long before submission. Differences in CMC expectations can create gaps that surface late, leading to avoidable rework and delays. Join AsymBio’s upcoming webinar to explore what the FDA and NMPA expect at IND—and how a harmonized development package and filing strategy can streamline dual submissions. Key Learning Objectives- Understand why parallel US–China IND filing is becoming increasingly common for ADC programs.- Clarify CMC expectations at IND: what is required and what can wait.- Identify key technical differences between FDA and NMPA requirements.- Explore how one harmonized package and a dossier adaptable for English and Chinese submissions can support both markets. SpeakerXia Meng Head of Regulatory CMC, AsymBio With 14 years of experience in biologics CMC, Xia has worked across analytical development, CMC review at the CDE, and regulatory strategy. She has contributed to more than 60 antibody, recombinant protein, and ADC programs, with particular expertise in control strategy and multi-market filing harmonization. Scan the QR code below to register!

Webinar Invitation: ADC Process Challenges and Conjugation Technology AdvancesWhat stands between a promising ADC and commercial manufacturing?As bispecific and dual-payload ADCs advance, the challenge extends beyond molecular design. Process robustness, manufacturing capacity, and supply chain security are becoming central to bringing these programs to market.Join AsymBio’s upcoming webinar to explore the process challenges that can hold ADC programs back—and the cutting-edge conjugation technologies shaping their development.Key Learning Objectives- Identify challenges in scaling ADC manufacturing.- Explore conjugation advances for complex ADCs.- Understand CMC needs across development, manufacturing, and supply chains. SpeakerSong LiangSenior Director, Department of MSAT, AsymBioHead of MSAT at AsymBio, brings nearly a decade of experience in biopharmaceutical process development, including leading the scale-up of over six ADC projects.Scan the QR code below to register!

See you at the 17th World ADC San Diego!Stop by Booth 67 to share what you’re working on and hear what’s new at AsymBio.Connect with our team by scanning the QR code to arrange a meeting!

AsymBio will be exhibiting at Festival of Biologics Basel 2026, where we will share how our integrated CDMO capabilities support global clients from early development through commercial manufacturing.Scan the QR code to schedule a meeting with our team. Come and meet us at Booth 454 about your program and how AsymBio can support its next stage.

Behind today’s rapidly expanding clinical pipelines, CMC has emerged as one of the most critical factors determining whether an ADC can successfully reach the market. Recent FDA setbacks involving Chinese ADC assets have drawn significant industry attention, highlighting that CMC is no longer simply a back-office function, but a strategic priority that can influence company valuations, BD deal terms and long-term global competitiveness. Co-hosted by Healthcare Executive, Weijieyao, Asymchem and AsymBio, this panel brings together biotech executives and industry leaders from around the world to examine how CMC and manufacturing strategy influence an ADC’s path to commercial supply and global markets—covering manufacturing models, global regulatory compliance, supply-chain resilience and long-term competitiveness. What We Will CoverCMC – The Invisible Arbiter of ADC CommercializationThe Crossroads of Manufacturing Strategy – In-House, CDMO, or Hybrid?Global CMC Compliance – Navigating Regulatory Expectations Across MarketsSupply Chain Resilience – From Cost Efficiency to Strategic SecurityLooking Ahead – How CMC Will Shape the Next Generation of ADC Leaders September 29, 2026 11:00 AM ET | 8:00 AM PTCo-hosted by Healthcare Executive, Weijieyao, Asymchem and AsymBioRegistration is now open: Click to Register

AsymBio is heading to Boston for the Oncology & Immunology Innovation Partnering & Licensing Summit, September 9–10!We look forward to connecting with industry partners and exploring new opportunities in oncology and immunology.Scan the QR code to schedule a meeting with our team.See you in Boston!

Webinar Invitation: Phase-Appropriate Development and CMC Control Strategies of Biologics and ADCs The structural complexity of biologics and ADCs creates significant challenges in development and quality control. How can development teams apply the right level of CMC rigor at each phase while maintaining efficiency? Join our upcoming webinar to explore a phased, QbD- and risk-based approach to biologics and ADC development and CMC control. Key Learning Objectives:1. The principles of QbD-based CMC development strategy2. Phase-appropriate development strategy for CQA, specifications, analytical methods, process change and comparability3. Highlights of AsymBio’s growing global presence Speaker Dr. Zhaofeng DingExecutive Director, CMC Lead, AsymBio 15+ years of pharmaceutical development experience in the U.S. and China, with 50+ INDs and 10+ NDA/BLAs led and filed across mAbs, bsAbs, fusion proteins, ADCs and polypeptides. Click to Register

Webinar Invitation: Overcoming the Challenges in ADC Drug Product Development by Leveraging an Integrated PlatformAs antibody-drug conjugates (ADCs) continue to evolve with increasingly diverse antibody, linker, and payload designs, drug product (DP) development has become more complex than ever. Achieving a robust and scalable DP strategy requires balancing formulation, stability, manufacturing, dosage form, and clinical administration while addressing the unique characteristics of each ADC molecule.How can you overcome key drug product development challenges while accelerating development and ensuring product quality from early-stage development through commercialization?Join our upcoming webinar to explore practical strategies, integrated platform capabilities, and real-world case studies that support successful ADC drug product development in a CDMO environment.Key Learning ObjectivesCommon challenges in ADC drug product developmentStrategies to mitigate light- and oxidation-induced degradation of ADCsOptimization of lyophilized ADC drug product formulationsCustomized in-use evaluations to support clinical administrationSpeaker Shujing Wang Head of Drug Product Development, AsymBioClick to Register

We are thrilled to announce AsymBio’s partnership with the 4th ADC Linker & Conjugation Summit, taking place July 28–30, 2026 in Boston, MA — the industry’s premier gathering focused on payload-linker , bioconjugation, and next-gen ADC. Our team will be on-site to showcase AsymBio’s award winning Conjugation Toolbox. Backed by in-house payload-linker and antibody CMC capabilities, we deliver integrated solutions covering early-stage development through clinical and commercial ADC manufacturing. Connect with our team to shape the future of ADC together. See you in Boston!

AsymBio is proud to be an Exhibition Partner at the 5th Targeted Radiopharmaceuticals Summit US in San Diego (July 21–23, 2026)! AsymBio is the leading CDMO solutions provider in RDC landscape — from process development to late-stage CMC. Visit us at our booth to learn how AsymBio supports partners across the radiopharmaceutical journey with integrated services that accelerate progress from molecule to market.